Walleye Capital
CSTL icon

Walleye Capital’s Castle Biosciences CSTL Stock Holding History

Walleye Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-170,786
Closed -$2.88M – 5031
2023
Q3 		$2.88M Buy
+170,786
New +$2.99M 0.01% 1442
2022
Q1 		– Sell
-13,443
Closed -$576K – 2344
2021
Q4 		$576K Buy
+13,443
New +$702K 0.02% 896
2021
Q2 		– Sell
-5,841
Closed -$400 – 1368
2021
Q1 		$400 Buy
+5,841
New +$439K 0.02% 667

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's CSTL Position: Q4 2023 in Review

Walleye Capital sold out of Castle Biosciences (CSTL) in Q4 2023, closing a stake of 170,786 shares — an estimated $2.88M sold.

Walleye Capital first reported a position in CSTL in Q1 2021 and held it in 3 quarters. The position peaked at $2.88M in Q3 2023. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2023.

  • Walleye Capital reported no remaining Castle Biosciences position as of Q4 2023 after selling out during the quarter.
  • Walleye Capital sold 170,786 Castle Biosciences shares in Q4 2023, an estimated $2.88M.
  • Walleye Capital first reported a position in Castle Biosciences in Q1 2021 and held it in 3 quarters.
  • Walleye Capital's Castle Biosciences position peaked at $2.88M in Q3 2023.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.